Understanding the Dose Regimen for Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma (MM) after Prior Proteasome Inhibitors (PIs) and Immunomodulatory Drugs (IMiDs): A Quantitative Pharmacologic Perspective

被引：2

作者：

Xu, Xu Steven ^{[1
]}

Yan, Xiaoyu ^{[1
]}

Puchalski, Thomas ^{[2
]}

Lonial, Sagar ^{[3
]}

Lokhorst, Henk M. ^{[4
]}

Voorhees, Peter M. ^{[5
]}

Liu, Kevin ^{[1
]}

Khan, Imran ^{[1
]}

Jansson, Richard ^{[2
]}

Ahmadi, Tahamtan ^{[2
]}

Ruixo, Juan Jose Perez ^{[6
]}

Zhou, Honghui ^{[2
]}

Clemens, Pamela L. ^{[2
]}

机构：

[1] Janssen Res & Dev LLC, Raritan, NJ USA

[2] Janssen Res & Dev LLC, Spring House, PA USA

[3] Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA USA

[4] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands

[5] Univ N Carolina, Lineberger Comprehens Canc Ctr, Div Hematol Oncol, Chapel Hill, NC 27599 USA

[6] Janssen Res & Dev, Beerse, Belgium

来源：

关键词：

D O I：

10.1182/blood.V126.23.4254.4254

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 41 条